Neurocrine Biosciences, Inc.: stock overview

NBIXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$167.40

November 13, 2026Market cap $16.8B

DCF calculator

What Ploutos Investor adds for Neurocrine Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Neurocrine Biosciences had revenue of $3.7B over the last 12 months and net income of $703M, a net margin of 19.0%. Revenue grew by 22.3% a year on average over the last 5 years. At $167.40 the shares trade at a P/E of 23.9, against a median of 53.3 over the last 5 fiscal years. It holds more cash than debt, by $738M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$16.8B
100M shares
P/E
23.9
Today23.9
Median53.3
Revenue, 12 months
$3.7B
+22.3% a year over 5 years
Net margin
19.0%
2025: 16.7%, above 86% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+23.1% a year over 2 years

  • 202510-K
    Revenue$2.9B
  • 202410-K
    Revenue$2.4B
  • 202310-K
    Revenue$1.9B

Fiscal years in figures

NBIX's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $13.6B
$16.8B
Enterprise value 
$16.1B
P/E 3-year median: 41.5
23.9
EV / EBIT 
18.1
EV / Revenue 
4.3
P/B 3-year median: 5.3
4.3
FCF yield 3-year median: 4.1%
6.2%
Earnings yield 3-year median: 2.4%
4.2%

Profitability

Gross margin 
97.8%
Operating margin 
24.0%
Net margin 3-year median: 14.5%
19.0%
ROIC 
19.4%
ROIC, 5-year average 
11.2%
ROE 
20.4%

Growth

Revenue, yearly change 
+21.5%
EPS, yearly change 
+41.9%
FCF, yearly change 
+34.4%
Revenue, average a year 
+22.3%
EPS, average a year 
+2.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$738M
Total debt 
$452M
Of which operating leases 
$452M
Net cash 
$738M
Net debt / EBITDA 
-0.8x
Interest cover 
–
Current ratio 
2.04

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
1.00%
Total returned 
1.00%
Shares, yearly change 
+0.7%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

21.6%

Above 86% of the 285 companies in its industry, and 85% of all.

Net margin

16.7%

Above 86% of the 302 companies in its industry, and 78% of all.

ROE

14.7%

Above 75% of the 267 companies in its industry, and 75% of all.

ROA

10.3%

Above 81% of the 313 companies in its industry, and 88% of all.

Revenue growth

21.5%

Above 73% of the 292 companies in its industry, and 82% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
NEUROCRINE BIOSCIENCES INC
CIK
914475
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
100M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Neurocrine Biosciences's filings show?

These are Neurocrine Biosciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NBIX

Didn't find what you were looking for?

Ask us
What is NBIX's market cap?

Neurocrine Biosciences, Inc.'s market cap is $16.8B, at a price of $167.40 on November 13, 2026 and 100M shares.

What is NBIX's P/E?

NBIX's P/E is 23.9, on earnings per share of $6.74 over the last 12 months. The median over the last 5 fiscal years was 53.3.

How much revenue does NBIX have?

Neurocrine Biosciences had revenue of $3.7B over the last 12 months. Over the last 5 years it changed by +22.3% a year on average.

Does NBIX pay a dividend?

No. Neurocrine Biosciences paid no regular dividend over the last 12 months.

Where do the figures come from?

From Neurocrine Biosciences, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.